KINETIC-TECHNOLOGIES
15.11.2022 07:01:41 CET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced two new milestone products that can increase the Power Delivery capability of USB Type-C ports to 140W, removing the barrier to expanding the range of electronic products charged via USB. The KTS1898 is dedicated to switching and protecting VBUS power, while the KTU1128 is dedicated to switching and protecting the CC1/2 and SBU1/2 lines.
The KTS1898 is a low-resistance, 5A load switch with soft-start, overvoltage, “ideal diode” reverse-current, short-circuit, over-current, over-temperature and ESD protection plus integrated surge protection of ±100V, designed to isolate and protect downstream components from abnormal VBUS voltage and current conditions. The fast reverse current protection (ideal diode) allows multiple power paths to be connected to VBUS OUT without interference.
The KTU1128 companion IC is a Thunderbolt compatible, Type-C USB data line protection and switch IC, providing low-resistance, ultra-fast OVP, and surge protection for the CC and SBU lines. Maintaining pin-to-pin compatibility with existing products, the KTU1128 increases the operating tolerance on CC and SBU lines to 32V for short-to-VBUS protection and reduces the quiescent current.
“The KTS1898 and KTU1128 are industry leading devices that allow designers to implement USB Type-C PD3.1 Extended Power Range (EPR) up to 140W and effectively address safety at the same time,” says Erik Ogren, Kinetic Technologies Senior Director of Marketing. “With the ability to withstand up to +35V on VBUS, the KTS1898 delivers the margin our customers require to build 28V systems that are designed to be safe and reliable, while the super low-resistance 25mΩ MOSFET keeps heat to a minimum, which is essential when operating at such high-power levels. The KTU1128 features the same built-in robust protection and together extends Kinetic’s lead in this application.”
KTS1898 and KTU1128 samples are available now with production starting in first quarter 2023. Visit Kinetic Technologies for further information.
Key Product Highlights:
KTS1898 – 28V VBUS Protection
-
3V to 32V Operating Voltage Range
- 35V Abs Max. Rating at IN & OUT
-
5A Continuous Current Rating
- 10A peak
- Supports 140W USB Power Delivery 3.1 (EPR)
- “Ideal Diode” Reverse-current protection with 15µs fast recovery
- Full Protection: OVP, SCP, OCP, OTP & RCP
- IEC61000-4-5 Surge Protection ±100V
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
KTU1128 – 28V CC/SBU Protection
-
2.5V to 5.5V Operating Voltage Range
- 32V DC Tolerance on CC1/2, SBU1/2
- Thunderbolt Compatible
- Fast 70ns OVP response time
- IEC61000-4-5 Surge Protection ±40V/±30V CC/SBU
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005095/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom